Standards of care for anemia management in oncology: Focus on lung carcinoma

Cancer

Volumn 95, Issue 3, 2002, Pages 613-623

  Langer, Corey J ^a   Choy, Hak ^b   Glaspy, John A ^c   Colowick, Alan ^d  

^a FOX CHASE CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AMGEN INC   (United States)

Author keywords

Anemia; Darbepoetin ; Epoetin ; Fatigue; Lung carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; ETOPOSIDE; GEMCITABINE; MITOMYCIN C; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; SIALIC ACID; VINDESINE;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG USE; FATIGUE; HEMOGLOBIN DETERMINATION; HUMAN; INCIDENCE; LUNG CARCINOMA; MEDICAL LITERATURE; PRIORITY JOURNAL; STANDARD;

ANEMIA; BLOOD TRANSFUSION; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; LUNG NEOPLASMS; PLATINUM COMPOUNDS; QUALITY OF LIFE;

EID: 0036682105     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10712     Document Type: Article

References (82)

1. The causes and prognostic significance of low haemoglobin levels in tumor patients
2. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx
3. Implications of the anemia of chronic disorders in patients anticipating radiotherapy
4. Anaemia, fatigue and quality of life in advanced malignancy: Potential therapeutic role for epoetin
5. Retrospective analysis of hematological parameters and transfusion requirements in non-platinum chemotherapy-treated patients
6. A retrospective review of blood transfusions in cancer patients with anemia
7. Discussion
8. Erythropoietin decreases transfusion requirements during radiochemotherapy
9. Chemotherapy-induced anemia in adults: Incidence and treatment
10. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue
11. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis
12. Correlation of quality of life (QOL) with survival, treatment response and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel
13. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey
14. Anemia in cancer patients
15. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy
16. An epidemiclogical review of anaemia in cancer chemotherapy in Canada
17. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study
18. Chemotherapy of non-small-cell lung cancer: Role of erythropoietin in the management of anemia
19. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo
20. Pathophysiology of cancer-related anemia
21. Progress in understanding the pathogenesis of the anemia of chronic disease
22. Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production
23. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis
24. Cisplatin-associated anemia: An erythropoietin deficiency syndrome
25. Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells
26. Decreased erythropoietin response in patients with the anemia of cancer
27. Chemotherapy-induced anemia in patients with primary lung cancer
28. Radiotherapy-associated anemia: The scope of the problem
29. Risk of transfusion in small cell lung cancer patients receiving chemotherapy
30. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study
31. T1/T2 glottic cancer managed by external beam radiotherapy: The influence of pretreatment hemoglobin on local control
32. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix
33. The significance of anemia in clinical radiation therapy
34. The use of erythropoietin in radiation oncology
35. Oxygenation predicts radiation response and survival in patients with cervix cancer
36. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
37. Role of iron in optimizing responses of anemic cancer patients to erythropoietin
38. Impact of anemia in patients with head and neck cancer
39. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome
40. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas
41. The significance of anemia in clinical radiation therapy
42. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx
43. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind placebo-controlled trial
44. Is anemia a problem for European cancer patients and treating oncologists?
45. Impact of cancer-related fatigue on the lives of patients: New findings from the fatigue coalition
46. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer
47. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system
48. Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer
49. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
50. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
51. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy
52. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies
53. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoletin
54. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
55. Transfusion medicine. Part 1: Blood transfusion
56. Anaemia in cancer: Pathophysiology and treatment
57. Perioperative blood transfusion and colorectal cancer recurrence: A qualitative statistical overview and meta-analysis
58. Perioperative blood transfusions reduce long-term survival following surgery for colorectal cancer
59. Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma
60. Blood transfusions and prognosis in colorectal cancer
61. Prostate cancer recurrence in radical surgery patients receiving autologous or homologous blood
62. Erythropoietin and anemia of cancer
63. Clinical trial experience using erythropoietin during radiation therapy
64. Erythropoietin for anaemia in cancer patients
65. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer
66. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia
67. Cost of outpatient blood transfusion in cancer patients
68. Epoetin alfa practice pattern usage in community practice sites
69. The role of carbohydrate on the biological activity of erythropoietin
70. Biological roles of oligosaccharides: All of the theories are correct
71. Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO)
72. Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half-life in oncology patients
73. Novel erythropoiesis stimulating protein
74. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients
75. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or once every other week
76. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer
77. Randomized, double-blind, placebo controlled, phase I/II dose finding study of ARANESP™ administered once every three weeks in solid tumor patients
78. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: Preliminary report
79. A randomized, blinded, placebo-controlled, phase II, dose-finding study of NESP in patients with lymphoproliferative malignancies
80. Randomized, active-controlled, phase 1/2, dose-comparison study of NESP administered weekly or every 2 weeks in patients with solid tumors
81. A phase double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer
82. Open-label, phase I/II dose escalation study of NESP in patients with chronic anemia of cancer